CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 2 | 3 |
| 2001 | 3 | 2 | 5 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 5 | 6 |
| 2004 | 7 | 4 | 11 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 3 | 8 |
| 2007 | 4 | 3 | 7 |
| 2008 | 6 | 8 | 14 |
| 2009 | 10 | 5 | 15 |
| 2010 | 2 | 8 | 10 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 5 | 7 |
| 2013 | 8 | 3 | 11 |
| 2014 | 7 | 5 | 12 |
| 2015 | 6 | 3 | 9 |
| 2016 | 4 | 4 | 8 |
| 2017 | 6 | 5 | 11 |
| 2018 | 5 | 7 | 12 |
| 2019 | 15 | 11 | 26 |
| 2020 | 7 | 13 | 20 |
| 2021 | 15 | 12 | 27 |
| 2022 | 6 | 21 | 27 |
| 2023 | 3 | 7 | 10 |
| 2024 | 11 | 11 | 22 |
| 2025 | 6 | 13 | 19 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Chemotherapy-induced activation of caspase-1 and IL-1a release by cancer cells remotely skews myelopoiesis to drive pro tumorigenic systemic neutrophil-dominant inflammation. Nat Commun. 2026 Apr 20; 17(1).
-
CD8 TRM-like T cells expressing perforin and IFN-? define a pediatric activated T-cell acute liver failure endotype. Hepatol Commun. 2026 Apr 01; 10(4).
-
MHC class I on target cells regulates CD4+ T cell-mediated immunity. Nat Immunol. 2026 May; 27(5):1000-1012.
-
Mitochondrial complex II orchestrates divergent effects in CD4+ and CD8+ T cells. J Clin Invest. 2025 Dec 15; 135(24).
-
Identification of immunogenic KIF5B-RET fusion neopeptides driving immune stimulation in tumor specific CD8+ T cells. Front Immunol. 2025; 16:1635810.
-
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025 11; 647(8089):488-497.
-
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. Nat Commun. 2025 Oct 13; 16(1):9090.
-
Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat Commun. 2025 Sep 30; 16(1):8696.
-
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial. Nat Commun. 2025 Sep 29; 16(1):8567.
-
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia. 2025 12; 39(12):3004-3014.